Small molecule MYC Inhibitor restricts ovarian tumor growth by suppressing c-Myc mediated glycolysis

This suppression is accompanied by the promotion of p53 and pro-apoptotic markers, indicating a potential induction of cancer cell apoptosis. Notably, GD-07 exhibit superior efficacy to carboplatin in patient-derived organoids of high-grade serous ovarian cancer (HGSOC), effectively mimicking clinical responses. GD-07 disrupts metabolic pathways and induces apoptosis by modulating key oncogenic and tumor suppressor genes.

Our findings highlight GD-07 as a promising therapeutic agent that selectively targets the c-Myc G-quadruplex and disrupts bioenergetics, offering a dual mechanism of action by inhibiting proliferation and promoting apoptosis. GD-07 represents a novel approach with high translational potential for treating resistant and metastatic ovarian cancer, laying the foundation for future development of next-generation cancer therapeutics.